Prime Medicine, Inc. (NASDAQ: PRME) reported Q2 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.